BioSpace News Archive

Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced the publication of a manuscript detailing the study design and methodology for its pivotal clinical trial of BT-001 in adult patients with type 2 diabetes (T2D) in the medical journal, Clinical Cardiology.

The global antibody production market size is expected to reach USD 37.81 Billion in 2030 and register a revenue CAGR of 14.4% over the forecast period, according to the latest report by Reports and Data.

The global cancer biomarker market size is expected to reach USD 118.08 Billion in 2030 and register a revenue CAGR of 17.6% over the forecast period, according to the latest report by Reports and Data.

Forecast to 2030,’ thoroughly examines the Brain Reading Robots industry to provide essential data & information for the targeted readers.

According to the current analysis of Reports and Data, the global Computational Biology market was valued at USD 5.35 Billion in 2021 and is expected to reach USD 29.49% Billion by the year 2030, at a CAGR of 29.49 % .

The global genome editing market size is expected to reach USD 30.23 billion in 2030 and register a CAGR of 18.2% over the forecast period, according to the latest report by Reports and Data.

The global genomics market size is expected to reach USD 129.34 Billion in 2030 and register a revenue CAGR of 19.0% over the forecast period, according to the latest report by Reports and Data.

Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company committed to improving health equity for seniors, today announced that it will report second quarter 2022 financial results after market close on Monday, August 8, 2022.

Connect Biopharma Holdings Limited announced it has been informed by the Center for Drug Evaluation of the National Medical Products Administration, that it can conduct primary analysis of its ongoing pivotal trial for its lead product candidate CBP-201 to treat adult patients with moderate-to-severe atopic dermatitis based on the 255 patients already enrolled.

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), today announced that Chief Medical Officer, Christopher Morabito, M.D., will be leaving the company, effective July 13, 2022. Judith Dunn, Ph.D., President of Research and Development will provide interim leadership while the executive search for a new CMO is ongoing.